Literature DB >> 17303655

Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice.

Sang Jun Han1, Sophia Y Tsai, Ming-Jer Tsai, Bert W O'Malley.   

Abstract

RU486 is an incomplete progesterone receptor (PR) antagonist due to its partial agonist activity. To investigate the tissue-specific effects of RU486 on PR function in an ovariectomized mouse model, we used the progesterone receptor activity indicator mouse and evaluated the key determinants of progesterone-dependent gene activity: PR, coregulators, and kinases. As might be expected, acute RU486 treatment (6 h after injection) reduced PR transcriptional activity in the uterus, compared with vehicle or progesterone (P4) treatments. Chronic RU486 treatment (3 d) had a distinctly different effect on PR-mediated transcription, elevating PR activity in both the uterus and mammary gland, whereas chronic P4 treatment reduced PR activity in both tissues. This elevated uterine PR activity was associated with increased modified forms of PR and total protein levels of steroid receptor coactivator (SRC)-1 without affecting SRC-2 or SRC-3 protein levels. In addition to increased levels of coactivators, chronic RU486 treatment activated the ERK-1/2 and c-Jun N-terminal kinase signaling pathways in the uterus in a manner comparable with P4 treatment. In contrast to our observations in the uterus, chronic RU486 treatment increased modified forms of PR and the SRC-3 protein levels (but not SRC-1 and SRC-2 levels) in luminal epithelial cells of the mammary gland. Chronic RU486 also activated the c-Jun N-terminal kinase, but not ERK-1/2, signaling pathways in mammary luminal epithelial cells. This report suggests that in comparison with chronic natural hormone (P4), a mixed antagonist/agonist (RU486) induces a distinct temporal and spatial pattern of cellular genetic regulators that accompany ligand-specific gene expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303655     DOI: 10.1210/en.2006-1561

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

1.  Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity.

Authors:  Larbi Amazit; Audrey Roseau; Junaid A Khan; Anne Chauchereau; Rakesh K Tyagi; Hugues Loosfelt; Philippe Leclerc; Marc Lombès; Anne Guiochon-Mantel
Journal:  Mol Endocrinol       Date:  2011-01-27

2.  Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.

Authors:  Suzanne E Wardell; Dmitri Kazmin; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2012-05-08

Review 3.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

4.  Steroid receptor coactivator-2 expression in brain and physical associations with steroid receptors.

Authors:  M A Yore; D Im; L K Webb; Y Zhao; J G Chadwick; H A Molenda-Figueira; S J Haidacher; L Denner; M J Tetel
Journal:  Neuroscience       Date:  2010-06-02       Impact factor: 3.590

5.  Steroid receptor coactivator-1 from brain physically interacts differentially with steroid receptor subtypes.

Authors:  Heather A Molenda-Figueira; Suzanne D Murphy; Katherine L Shea; Nora K Siegal; Yingxin Zhao; Joseph G Chadwick; Larry A Denner; Marc J Tetel
Journal:  Endocrinology       Date:  2008-06-19       Impact factor: 4.736

Review 6.  Tracking progesterone receptor-mediated actions in breast cancer.

Authors:  Todd P Knutson; Carol A Lange
Journal:  Pharmacol Ther       Date:  2013-11-26       Impact factor: 12.310

7.  Up-regulation of circadian clock gene Period 2 in the prostate mesenchymal cells during flutamide-induced apoptosis.

Authors:  Kaoru Yoshida; Pei-Jian He; Nobuhiko Yamauchi; Seiichi Hashimoto; Masa-Aki Hattori
Journal:  Mol Cell Biochem       Date:  2009-08-28       Impact factor: 3.396

8.  Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model.

Authors:  Nathalie Esber; Clément Cherbonnier; Michèle Resche-Rigon; Abdallah Hamze; Mouad Alami; Jérôme Fagart; Hugues Loosfelt; Marc Lombès; Nathalie Chabbert-Buffet
Journal:  Horm Cancer       Date:  2016-03-03       Impact factor: 3.869

9.  Rethinking progesterone regulation of female reproductive cyclicity.

Authors:  Kaiyu Kubota; Wei Cui; Pramod Dhakal; Michael W Wolfe; M A Karim Rumi; Jay L Vivian; Katherine F Roby; Michael J Soares
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

10.  Influence of progesterone on endometrial nitric oxide synthase expression.

Authors:  Omid Khorram; Guang Han
Journal:  Fertil Steril       Date:  2008-08-16       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.